

# 1 APPENDIX R- Declarations of interests

## 2 1.1 Introduction

3 All members of the GDG and all members of the NCGC staff were required to make  
4 formal declarations of interest at the outset of each meeting, and these were updated at  
5 every subsequent meeting throughout the development process.

6 Declarations of interests of the GDG members

7	Dr Nick Kosky.....	p.2
8	Professor Helen Cross.....	p. 3
9	Mrs Tracey Truscott.....	p.4
10	Mrs Diane Flower.....	p.5
11	Professor John Duncan.....	p.6
12	Dr Margaret Jackson.....	p.7
13	Dr Richard Appleton.....	p.8
14	Dr Greg	
15	Rogers.....	p.10
16	Mr Sean	
17	Mackey.....	p.11
18	Mr Michael	
19	Harnor.....	p.12
20	Mrs Sally	
21	Gomersall.....	p.13
22	Dr Amanda	
23	Freeman.....	p.14
24	Dr Ian Wong.....	p.15
25	Michael	
26	Marsh.....	p.16

1	Dr Aza	
2	Abdulla.....	p.17
3	Professor Frank	
4	Besag.....	p.18

5

6 **1.1.1 Dr Nick Kosky**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	None directly relevant. Sits on a variety of advisory boards and speaker panels for the pharmaceutical industry, but these relate to antidepressants and antipsychotics and the treatment of psychosis, mood and anxiety disorders. Has no involvement with the development, marketing, surveillance of anticonvulsants or, save where they are used in the treatment of bipolar disorder, teaching or training concerning these drugs. As part of the appointment, all remunerated activities with the pharmaceutical company will cease. Any relationship with a manufacturer of an anticonvulsant will cease.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare.
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

7

8

1

**1.1.2 Professor Helen Cross**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	Educational grants for travel and honoraria for lectures received from UCB, Eisai SHS International and Janssen Cilag. Contribution to funding of an annual 'Epilepsy Training Fellowship' within the Neuroscience Unit, Great Ormond Street Hospital for Children NHS Trust by Janssen Cilag, UCB and Eisai. Medical advisor to 'Matthews Friends' a parent support group for families of children on the ketogenic diet.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	13.09.09- Nutricia Symposium at EFND. 16.09.09 Education talk on Ketogenic diet for Nutricia, Honoraria department.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Conducted educational lectures for Neutricia (Sept 09, Florence and a webinar) and UCB (Leuven) October 2009. Honorarium paid to the department (Neurosciences Unit UCL-ICH).  A co-author of one of the Ketogenic Diet studies.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare
<b>Tenth GDG Meeting (10<sup>th</sup> June 2010)</b>	Talk at Educational Symposia Sponsored by VCB Honorarium Department. Reporting as expert in review of Sodium Valproate use in pregnancy. Expert in Neurological Outcome review in 10 test cases.  Expert witness for sanofi in the litigation case on effect of sodium valproate on unborn child, all funds going to the department Spoke at an SHS symposia in Egypt at ICNA on ketogenic diet but did not receive payment.  A co-author of one of the Ketogenic Diet studies.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	
<b>Actions</b>	At the November 2009 and 10 <sup>th</sup> June GDG meetings, Helen acted as an expert on Ketogenic Diet and not as a GDG member when discussing recommendations related to the ketogenic diet.

2

3

1

**1.1.3 Mrs Tracey Truscott**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	UCB drug representative provides light refreshments for monthly Kent and Kings Specialist nurse meetings for which I attend. An epilepsy master class was held in April 2009. UCB sponsored all attendees.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Attendance at Best Value, Better Care Commissions Epilepsy services 23/12/10. A one to one meeting with the UCB rep to discuss Buccal Midazolam
<b>Tenth GDG Meeting (10<sup>th</sup> June 2010)</b>	Attendance at epilepsy master class sponsored by UCB
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

1

**1.1.4 Mrs Diane Flower**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	In addition to her role as lead children's epilepsy specialist nurse in Newport, she is now also working part-time as tuberous sclerosis specialist nurse at the RUH in Bath.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Has organised a study day (13 <sup>th</sup> May) for 20 people and lunch will be paid for by Special Products (Does not know the exact cost). She also attended a meeting on the 22 <sup>nd</sup> March that was sponsored by Esai and UCB pharma.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Did not attend
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	Colleague on my team has applied for funding (approx £300) from UCB pharma to attend a conference
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

1

**1.1.5 Professor John Duncan**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	Previous lecture fees from UCB Pharma, Janssen-Cilag. Advisory Boards for Sanofi Aventis, Eisai, GlaxoSmithKline, GE Healthcare. Grants to support research and education events from UCB Pharma, GlaxoSmithKline, Eisai, Janssen- Cilag.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	EISAI/UCB/Janssen – fees to UCL for arranging meetings and giving lectures.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Attended the ABPI Annual dinner on the 27 <sup>th</sup> April at the invitation of UCB.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Did not attend
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	Fee paid to UCL to chair and speak at Satellite Symposium at European Epilepsy Congress, 27 June 2010. Travel , accommodation and Conference registration paid by Glaxo Smith Kline (GSK).
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

4

1

**1.1.6 Dr Margaret Jackson**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No non-personal pecuniary interests within the last 12 months- the neurology department received £15000 from UCB 15 months ago to support the construction of a database for patients with epilepsy. No personal non-pecuniary interests within the last year. I have done review articles in the past on management of epilepsy expressing views on drug management for peer-reviewed journals.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	UCB will be sponsoring a regional epilepsy meeting on September 18 <sup>th</sup> for Newcastle/Middlesborough.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Giving a presentation on the 12 <sup>th</sup> November 2009 on neurodevelopment and epilepsy to SpRs funded by Esai, with the honorarium going to the research fund. Also attending a UCB sponsored meeting in Hampshire later in November.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare.
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	No interests to declare.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

## 1 1.1.7 Dr Richard Appleton

GDG meeting	Declaration of Interests
<b>On Application</b>	I have, within the past five years received honoraria and consultancy fees from the following pharmaceutical companies: Eisai, GlaxoSmithKline, Janssen-Cilag, Parke-Davis, Sanofi-Aventis, Special Products Ltd, UCB Pharma. I have no current active or ongoing pecuniary interests or pecuniary commitments/contracts with the pharmaceutical industry.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	I have within the past four weeks (April 6 <sup>th</sup> 2009) had confirmation that a pharmaceutical company, Eisai, will sponsor a booklet on 'Epilepsy for siblings' that I am co-editing with a Clinical Psychologist. The sponsorship is for the publication costs of the book and I will receive no financial 'reward' or like reward for publishing the book. There will be no royalties arising from the book which will be distributed free of charge.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	Did not attend
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Recent advice and consultations (as yet unpaid) provided to a new pharmaceutical company (Mitovie) regarding the introduction of a new formulation of emergency medication to treat tonic clonic seizures including convulsive status epilepticus. These consultations will continue and in 2010 are likely to be more formally based with advisory or consultancy fees.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	<p>Has been invited to speak, with honoraria, at the following academic meetings in May:</p> <ul style="list-style-type: none"> <li>• Epilepsy Masterclass; a series of tutorials on the transitional care of young people with epilepsy and learning difficulties sponsored by UCB. <b>No action required.</b></li> <li>• A one-day course on Paediatric Epilepsy sponsored by Healthcare Education Services for the pharmaceutical industry (this two-day course is arranged by Healthcare Services and is attended by representatives of those pharmaceutical companies who manufacture, or who are in the process of developing novel antiepileptic drugs). <b>No action required.</b></li> </ul>
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG meeting 14<sup>th</sup> May 2010</b>	Did not attend



<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	<p>Secretary of the local (Merseyside, North Wales and Cheshire) paediatric epilepsy network, called 'EPIC' (Epilepsy In Children). This network has been running for 10 years and one pharmaceutical company meets the costs of the meetings (hire costs of the venue, A-V equipment and evening buffet) for two consecutive years, after which sponsorship is taken on by another company. UCB Pharma is sponsoring EPIC for 2009 and 2010</p> <p>Has been asked to provide some consultancy work for GSK from July 2010. This will relate to work on a novel antiepileptic drug, and not on one of GSK's current and licensed antiepileptic drugs.</p> <p>Will be running a series of seminars (an 'Epilepsy Masterclass') on the transition of young people with epilepsy with learning difficulties from paediatric to adult care in September 2010. Will receive a single honorarium for this 'Epilepsy Masterclass' from UCB.</p> <p>Principal Investigator for two RCTs included in the scope of this guideline- vigabatrin in infantile spasms and gabapentin in partial seizures.</p>
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	
<b>Actions</b>	<p>As principal Investigator for two RCTs included in the scope of this guideline- vigabatrin in infantile spasms and gabapentin in focal seizures, Dr Appleton acted as an expert and not as a GDG member at the June 2010 GDG meeting when discussing recommendations related to infantile spasms and focal seizures.</p>

1

2

1

## 1.1.8 Dr Greg Rogers

GDG meeting	Declaration of Interests
<b>On Application</b>	Resigned from being a UCB advisor on July 22 <sup>nd</sup> 2008 when joining the TLOC GDG and have not received any payment. Editor of Synapse Primary Care neurological magazine sponsored by UCB/Orion/GSK. Received £700 last year for this- the publication is supported by an unconditional grant from UCB. Have contacted the company Oyster who publish the magazine and asked for payment to cease until 2010 when the GDG work is complete. Sponsorship to attend ILAE Conference in Berlin Autumn 08 by UCB. East Kent Epilepsy team meeting sponsored by UCB however the last time payment was accepted was 20 <sup>th</sup> March 2008 for £1000. So far it has only been UCB who have been involved however if acceptable I will approach other pharmaceutical companies to vary the sponsorship. One alternative is to approach the PCT. Invite to Hungarian ILAe meeting in June by Eisai, which has been declined and I do not plan to take up any offers while working on this GDG. Previously medical advisor for UCB. Honorarium from Royal Society of Medicine Autumn 08 talk on Blackouts. Plan to attend the ILAE GPwSI meeting in May. It is going to be hosted by the ILAE however it is sponsored by Eisai. Previously director of Primary Care Neurological Society. Clinical Advisor for Epilepsy Action and Epilepsy Bereaved.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Appointment to Panel B of the Guideline Review Panel
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	Did not attend
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Did not attend
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	On May 13 <sup>th</sup> gave an update on Epilepsy at the Imperial College GP update meeting with an honorarium of £150. <b>No action required.</b>
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	No interests to declare.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

1

**1.1.9 Mr Sean Mackey**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	I have received funding from Consultancy companies providing advisory panels on behalf of the Pharmaceutical Industry, but none for antiepileptic medication.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Facilitated and spoke at national events around the National Patient Safety Association Rapid Response Alerts around Strong Opioids, hosted by Pharmacy Management and sponsored by Napp pharmaceuticals. Paid directly by Pharmacy Management Limited.  Participated in an Advisory Panel around the use of Ezetimibe hosted by HGS Consultancy and sponsored by Schering Plough.  Expect to be involved in consultancy work that may be indirectly/directly funded by the Pharmaceutical Industry over the next 12 months but not associated with AEDs or Epilepsy.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	Did not attend
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Did not attend
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	Resigned from GDG due to personal reasons

2

3

1

**1.1.10 Mr Michael Harnor**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	I have stocks and share ISA administrated on a nominee basis by Barclays. This contains 37 ord shares in Astra Zeneca, 56 ord shares in GlaxoSmithKline and 197 ord shares in Smith and Nephew. Also 440 ord shares in Finsbury Worldwide Pharmaceutical Trust. I am national Chairman and senior trustee of The British Epilepsy Association (working name 'Epilepsy Action'): a registered charity and company limited by guarantee. We obtain from time to time donated funds from pharmaceutical companies but the Association operates a strict sponsorship policy which limits the proportion of our funds obtained from such sources and also strictly confines the purpose to which such funds can be put. Such funds are always used solely to further our particular charitable objective. We would also expect any supporters to be adhering to the industry codes of practice.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Did not attend
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	The Commission on Human Medicines has reduced its Expert Advisory Groups into a smaller number. The neurology EAG no longer exists. However, he is now Lay Member of the neurology, pain and psychiatry Expert Advisory Group. This means that he remains a lay member at the MHRA which hosts the CHM.
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	1) Has been appointed to the Commission on Human Medicines Expert Advisory Group on Neurology, Pain and Psychiatry. This will extend to 2013.  2) On 23rd February 2010, he attended with no venue costs a London conference 'Better Value, Better Care - Commissioning Epilepsy Services' which was substantially funded by UCB Pharma.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare.
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	6 <sup>th</sup> July Manchester. Will attend and contribute to the north west regional follow up of 'Better Value, Better Care – Commissioning Epilepsy Services'. Venue and subsistence costs paid by UCB Pharma.
<b>Tenth GDG Meeting (21st October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

1            **1.1.11        Mrs Sally Gomersall**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare. Interest declared on the 1 <sup>st</sup> March 2009- Recently been filmed for an educational DVD; Taking the Tablets, funded by an education grant from Janssen Cilag.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare.
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Will speak at the Best Value, Better Care – Commissioning Epilepsy Services conference on Tuesday 23 February 2010 Holiday Inn London - Kensington Forum. The conference is funded by UCB
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	On 2.7.09 I was elected to the Executive Committee at the Joint Epilepsy Council
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

4

5

6

7

8

9

10

11

12

13

**1.1.12        Dr Amanda Freeman**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
--------------------	---------------------------------

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Declaration of membership to the Epilepsy action Professionals Advisory Panel
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare.
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	No interests to declare.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	I have recently organised a Regional Paediatric Epilepsy Interest Group Meeting with total sponsorship amounting to £1500 approx to ensure that the meeting is free for non-medical staff, from the following companies: UCB, Cyberonics, Janssen-Cilag.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Did not attend. However, still declared that received £250 from Eisai in her capacity as Chair of the Wessex Paediatric Neurosciences Group to pay for room hire for their Multidisciplinary Regional Paediatric Epilepsy Study Day. The Rep also recently provided a sandwich lunch for our Departmental Grand Round. No action required.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Departmental 'Ground Round' Sponsorship (lunch only), UCB Pharma and SHS International. Regional Epilepsy Interest Group Meeting (£1000 UCB). Member of Epilepsy Action Professionals Advisory Panel (ongoing)
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	No interests to declare.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	
<b>Twelfth GDG Meeting (date)</b>	

1

2

3

4

5

6

7

8

9

1

2

**1.1.13 Dr Ian Chi Kei Wong**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Did not attend
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Did not attend
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	Did not attend
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	Did not attend
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Did not attend
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	Director and Founder: A School of Pharmacy, University of London Spin-out company 'Therakind' which is currently developing buccal midazolam for seizure treatments. Expert witness: Arnold and Porter LLP, a legal case related to epilepsy treatment. He has published several papers which reported that the treatments and research of epilepsy need to be improved.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	No interests to declare.
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	Director and Founder: A School of Pharmacy, University of London Spin-out company 'Therakind' which is currently developing buccal midazolam for seizure treatments.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	
<b>Actions</b>	At the June 2010 GDG meeting, Professor Wong acted as an expert and not as a GDG member when discussing recommendations related to buccal midazolam.

3

4

5

6

7

8

9

10

1            **1.1.14      Michael Marsh**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Did not attend
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Did not attend
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	Did not attend
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	Did not attend
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Did not attend
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Did not attend
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Did not attend
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

4

5

6

7

8

9

10



1            **1.1.15      Dr Aza Abdulla**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Did not attend
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Did not attend
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	Did not attend
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	Did not attend
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Did not attend
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	Member of the Clinical Effectiveness and Practice Committee of the British Geriatric Society
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Did not attend
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Did not attend
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	
<b>Eleventh GDG Meeting (date)</b>	

2

3

4

5

6

7

8

9

10

11

1            **1.1.16      Professor Frank Besag**

<b>GDG meeting</b>	<b>Declaration of Interests</b>
<b>On Application</b>	No interests to declare.
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	Did not attend
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	Did not attend
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	Did not attend
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Did not attend
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	Did not attend
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	Did not attend
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	Frank Besag has received lecture fees, consultancy fees, research grants and equipment grants from and has been sponsored to conferences by various pharmaceutical companies. He was previously editor-in-chief of a journal sponsored by GSK. He is currently receiving no monies from pharmaceutical companies, nor from any source other than his employer, the NHS in the UK.
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	Did not attend
<b>Ninth GDG Meeting 14<sup>th</sup> May 2010</b>	Did not attend
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	Did not attend
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	Did not attend
<b>Eleventh GDG Meeting (date)</b>	Did not attend

2

3

4

5

6

7

8

9

10

11

12

13

1 **1.2 Declarations of interests of the NCGC members**

2

<b>GDG meeting</b>	<b>Declaration of Interests of the NCGC members</b>
<b>On Application</b>	No interests to declare
<b>First GDG meeting (12<sup>th</sup> May 2009)</b>	No interests to declare
<b>Second GDG Meeting (14<sup>th</sup> July 2009)</b>	No interests to declare.
<b>Third GDG Meeting (17<sup>th</sup> September 2009)</b>	No interests to declare
<b>Fourth GDG Meeting (6<sup>th</sup> November 2009)</b>	Vanessa Nunes: Her partner is currently the director of a consultancy company for health economics and outcomes research and the company works with several pharmaceutical companies. There is however a clause in the contracts , which stipulates that the companies and pharmaceuticals they are working on are confidential.
<b>Fifth GDG Meeting (11<sup>th</sup> December 2009)</b>	No interests to declare.
<b>Sixth GDG Meeting (2<sup>nd</sup> February 2010)</b>	No interests to declare
<b>Seventh GDG Meeting (11<sup>th</sup> March 2010)</b>	No interests to declare
<b>Eight GDG Meeting (29<sup>th</sup> April 2010)</b>	No interests to declare.
<b>Ninth GDG Meeting (10<sup>th</sup> June 2010)</b>	No interests to declare.
<b>Tenth GDG Meeting (21<sup>st</sup> October 2010)</b>	

3